Addressing Generic-Drug Market Failures - The Case for Establishing a Nonprofit Manufacturer

N Engl J Med. 2018 May 17;378(20):1857-1859. doi: 10.1056/NEJMp1800861.

Authors

Dan Liljenquist¹, Ge Bai¹, Gerard F Anderson¹

Affiliation

¹ From Intermountain Healthcare, Salt Lake City (D.L.); the Johns Hopkins Carey Business School, Washington, DC (G.B.); and the Johns Hopkins Bloomberg School of Public Health, Baltimore (G.F.A.).

PMID: 29768140
DOI: 10.1056/NEJMp1800861

No abstract available

MeSH terms

Drug Costs
Drug Industry / economics*
Drugs, Generic / economics*
Economic Competition*
Humans
Organizations, Nonprofit
United States

Substances

Drugs, Generic